Background and Purpose Palmitoylethanolamide (PEA) acts via several targets, including cannabinoid CB1 and CB2 receptors, transient receptor potential vanilloid type-1 (TRPV1) ion channels, peroxisome proliferator-activated receptor alpha (PPAR α) and orphan G protein-coupled receptor 55 (GRR55), all involved in the control of intestinal inflammation. Here, we investigated the effect of PEA in a murine model of colitis. Experimental Approach Colitis was induced in mice by intracolonic administration of dinitrobenzenesulfonic acid (DNBS). Inflammation was assessed by evaluating inflammatory markers/parameters and by histology; intestinal permeability by a fluorescent method; colonic cell proliferation by immunohistochemistry; PEA and endocannabinoid levels by liquid chromatography mass spectrometry; receptor and enzyme mRNA expression by quantitative RT-PCR. Key Results DNBS administration caused inflammatory damage, increased colonic levels of PEA and endocannabinoids, down-regulation of mRNA for TRPV1 and GPR55 but no changes in mRNA for CB1, CB2 and PPARα. Exogenous PEA (i.p. and/or p.o., 1 mg·kg-1) attenuated inflammation and intestinal permeability, stimulated colonic cell proliferation, and increased colonic TRPV1 and CB1 receptor expression. The anti-inflammatory effect of PEA was attenuated or abolished by CB2 receptor, GPR55 or PPARα antagonists and further increased by the TRPV1 antagonist capsazepine. Conclusions and Implications PEA improves murine experimental colitis, the effect being mediated by CB2 receptors, GPR55 and PPARα, and modulated by TRPV1 channels.

Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent / Borrelli, Francesca; Romano, Barbara; Petrosino, S; Pagano, Ester; Capasso, Raffaele; Coppola, D; Battista, G; Orlando, P; Di Marzo, V; Izzo, ANGELO ANTONIO. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - 172:1(2015), pp. 142-158. [10.1111/bph.12907]

Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent.

BORRELLI, FRANCESCA
Co-primo
;
ROMANO, BARBARA
Co-primo
;
PAGANO, ESTER;CAPASSO, RAFFAELE;IZZO, ANGELO ANTONIO
Ultimo
2015

Abstract

Background and Purpose Palmitoylethanolamide (PEA) acts via several targets, including cannabinoid CB1 and CB2 receptors, transient receptor potential vanilloid type-1 (TRPV1) ion channels, peroxisome proliferator-activated receptor alpha (PPAR α) and orphan G protein-coupled receptor 55 (GRR55), all involved in the control of intestinal inflammation. Here, we investigated the effect of PEA in a murine model of colitis. Experimental Approach Colitis was induced in mice by intracolonic administration of dinitrobenzenesulfonic acid (DNBS). Inflammation was assessed by evaluating inflammatory markers/parameters and by histology; intestinal permeability by a fluorescent method; colonic cell proliferation by immunohistochemistry; PEA and endocannabinoid levels by liquid chromatography mass spectrometry; receptor and enzyme mRNA expression by quantitative RT-PCR. Key Results DNBS administration caused inflammatory damage, increased colonic levels of PEA and endocannabinoids, down-regulation of mRNA for TRPV1 and GPR55 but no changes in mRNA for CB1, CB2 and PPARα. Exogenous PEA (i.p. and/or p.o., 1 mg·kg-1) attenuated inflammation and intestinal permeability, stimulated colonic cell proliferation, and increased colonic TRPV1 and CB1 receptor expression. The anti-inflammatory effect of PEA was attenuated or abolished by CB2 receptor, GPR55 or PPARα antagonists and further increased by the TRPV1 antagonist capsazepine. Conclusions and Implications PEA improves murine experimental colitis, the effect being mediated by CB2 receptors, GPR55 and PPARα, and modulated by TRPV1 channels.
2015
Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent / Borrelli, Francesca; Romano, Barbara; Petrosino, S; Pagano, Ester; Capasso, Raffaele; Coppola, D; Battista, G; Orlando, P; Di Marzo, V; Izzo, ANGELO ANTONIO. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - 172:1(2015), pp. 142-158. [10.1111/bph.12907]
File in questo prodotto:
File Dimensione Formato  
PEA 2015.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Accesso privato/ristretto
Dimensione 2.39 MB
Formato Adobe PDF
2.39 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/586487
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 139
  • ???jsp.display-item.citation.isi??? 130
social impact